MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
![Foto de MIGUEL JOSÉ](/img/nophoto.png)
![Foto de Hospital Universitario de Basurto](/img/noimage_org.png)
Hospital Universitario de Basurto
Bilbao, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de Basurto (6)
2022
2019
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2017
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
2007
-
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: A negative outcome study by the Spanish breast cancer research group (GEICAM)
Breast Cancer Research and Treatment, Vol. 101, Núm. 2, pp. 215-223
2006
-
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212